Holiferm invites applications from inspired, innovative and outstanding individuals for a full time process engineering role in biosurfactant production.
Holiferm is facilitating the transition of the $36 billion surfactant market from harmful, oil based chemicals to biobased alternatives by working with the current market leaders to provide a collaborative innovation platform.
Holiferm recently agreed its first technology license with a field leading surfactant company and received VC funding, positioning us to significantly grow the business, enabling technology scale up and the application of our technology to molecules of interest in collaboration with a number of production companies, all activities in which the applicant will play a key role.
We believe collaboration between companies, disciplines and individuals are the best ways to develop the biosurfactant industry and our company, and the applicant will have the opportunity to broaden their skill set by working with field leaders around the world, within a dynamic and friendly working environment. We offer a competitive pay package and benefits to attract incredible individuals to join our team and are currently based in Manchester, UK.
The successful candidate will be responsible for developing process control and scaling Holiferm’s breakthrough integrated production and gravity separation technology process to pre-industrial pilot scale. Scale up design work will be required as well as sourcing suitable facilities and engineering firms for construction of equipment. The appointee will work closely with fermentation team and customers, both to collaborate on fermentation development for additional molecules and to scale up the technology.
We are seeking highly motivated innovators who want to challenge themselves and others and fit well with our company philosophy, and first and foremost, get things done! The individual should have:
To apply, please send a CV with covering letter to email@example.com, or email for further information. Position intended to begin Q1-Q2 2019.